News stories about Peregrine Pharmaceuticals (NASDAQ:PPHM) have trended somewhat positive recently, AlphaOne Sentiment reports. The research firm, a division of Accern, rates the sentiment of media coverage by analyzing more than 20 million blog and news sources. AlphaOne ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Peregrine Pharmaceuticals earned a media sentiment score of 0.10 on AlphaOne’s scale. AlphaOne also gave news headlines about the biopharmaceutical company an impact score of 69 out of 100, meaning that recent media coverage is likely to have an impact on the stock’s share price in the next several days.

These are some of the news headlines that may have impacted AlphaOne Sentiment’s scoring:

Several equities research analysts have recently commented on the stock. Noble Financial reiterated a “buy” rating on shares of Peregrine Pharmaceuticals in a research note on Thursday, April 6th. Zacks Investment Research upgraded shares of Peregrine Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.25 price objective for the company in a research note on Thursday, December 22nd.

Peregrine Pharmaceuticals (NASDAQ:PPHM) traded down 0.7140% during midday trading on Tuesday, hitting $0.5423. 787,925 shares of the stock traded hands. Peregrine Pharmaceuticals has a one year low of $0.28 and a one year high of $0.77. The company has a 50-day moving average price of $0.66 and a 200 day moving average price of $0.42. The stock’s market cap is $161.45 million.

Peregrine Pharmaceuticals (NASDAQ:PPHM) last announced its earnings results on Monday, March 13th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, missing the consensus estimate of ($0.03) by $0.01. Peregrine Pharmaceuticals had a negative return on equity of 90.82% and a negative net margin of 80.49%. The business had revenue of $10.75 million for the quarter, compared to analysts’ expectations of $14.02 million. During the same period in the previous year, the company earned ($0.08) earnings per share. Peregrine Pharmaceuticals’s quarterly revenue was up 60.2% on a year-over-year basis. Equities research analysts anticipate that Peregrine Pharmaceuticals will post ($0.12) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This article was first reported by Daily Political and is the property of of Daily Political. If you are viewing this article on another site, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The correct version of this article can be viewed at

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc (Peregrine) is a biopharmaceutical company. The Company operates through two segments: Peregrine, which is engaged in the research and development of monoclonal antibodies for the treatment of cancer, and Avid, which is engaged in providing contract manufacturing services for third party customers on a fee-for-service basis while also supporting its internal drug development efforts.

5 Day Chart for NASDAQ:PPHM

Receive News & Ratings for Peregrine Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Peregrine Pharmaceuticals and related companies with's FREE daily email newsletter.